José Manuel Martínez

José Manuel Martínez

Auto-generated profile, based on publicly available information

José Manuel Martínez

Department of Gynecology and Obstetrics, Hospital Universitari de Bellvitge, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 June 2019 in International Journal of Cancer
Verified
Journal Article
Closed access
PDF file
LCLaura Costas
Laura Costas
JFJon Frias‐Gomez
Jon Frias‐Gomez
MGMagdalena Guardiola
Magdalena Guardiola
YBYolanda Benavente
Yolanda Benavente
MPMarta Pineda
Marta Pineda
OTon behalf of the Screenwide Team
on behalf of the Screenwide Team

1 July 2020 in Journal of Minimally Invasive Gynecology
Verified
Journal Article
Closed access
AGAmparo García-Tejedor
Amparo García-Tejedor
JMJose M. Martinez-Garcia
Jose M. Martinez-Garcia
BEBEATRIZ CANDÁS ESTÉBANEZ
BEATRIZ CANDÁS ESTÉBANEZ
ESElena Suarez
Elena Suarez
LMLaura Mañalich
Laura Mañalich
JPJordi Ponce
Jordi Ponce

1 April 2021 in European Journal of Obstetrics & Gynecology and Reproductive Biology
Verified
Journal Article
Closed access
JMJose M. Martinez-Garcia
Jose M. Martinez-Garcia
BEBEATRIZ CANDÁS ESTÉBANEZ
BEATRIZ CANDÁS ESTÉBANEZ
ESElena Suarez-Salvador
Elena Suarez-Salvador
MGMaria Gomez
Maria Gomez
EMElisabet Merino
Elisabet Merino
AGAmparo Garcia-Tejedor
Amparo Garcia-Tejedor

13 July 2023 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
LCLaura Costas
Laura Costas
IOIrene Onieva
Irene Onieva
BPBeatriz Pelegrina
Beatriz Pelegrina
FMFátima Marin
Fátima Marin
ÁCÁlvaro Carmona
Álvaro Carmona
SPSonia Paytubi
Sonia Paytubi
Purpose: Current diagnostic methods for endometrial cancer lack specificity, leading to many women undergoing invasive procedures. The aim of this study was to evaluate somatic mutations in urine to accurately discriminate patients with endometrial cancer from controls. Experimental Design: Overall, 72 samples were analyzed using next-generation sequencing (NGS) with molecular identifiers targeting 47 genes. We evaluated urine supernatant samples from women with endometrial cancer (n = 19) and age-matched controls (n = 20). Cell pellets from urine and plasma samples from seven cases were sequenced; further, we also evaluated paired tumor samples from all cases. Finally, immunohistochemical markers for molecular profiling were evaluated in all tumor samples. Results: Overall, we were able to identify mutations in DNA from urine supernatant samples in 100% of endometrial cancers. In contrast, only one control (5%) showed variants at a variant allele frequency (VAF) ≥ 2% in the urine supernatant samples. The molecular classification obtained by using tumor samples and urine samples showed good agreement. Analyses in paired samples revealed a higher number of mutations and VAF in urine supernatants than in urine cell pellets and blood samples. Conclusions: Evaluation of somatic mutations using urine samples may offer a user-friendly and reliable tool for endometrial cancer detection and molecular classification. The diagnostic performance for endometrial cancer detection was very high, and cases could be molecularly classified using these noninvasive and self-collected samples. Additional multicenter evaluations using larger sample sizes are needed to validate the results and understand the potential of urine samples for the early detection and prognosis of endometrial cancer.

Verified
Journal Article
Open access
PDF file
PPPaula Peremiquel-Trillas
Paula Peremiquel-Trillas
SPSonia Paytubi
Sonia Paytubi
BPBeatriz Pelegrina
Beatriz Pelegrina
JFJon Frias-Gomez
Jon Frias-Gomez
ÁPÁlvaro Carmona Pestaña
Álvaro Carmona Pestaña
LCLaura Costas
Laura Costas
Screenwide is a case-control study (2017–2021) including women with incident endometrial and ovarian cancers (EC and OC), BRCA1/2 and MMR pathogenic variant carriers, and age-matched controls from three centers in Spain. Participants completed a personal interview on their sociodemographic factors, occupational exposure, medication, lifestyle, and medical history. We collected biological specimens, including blood samples, self-collected vaginal specimens, cervical pap-brush samples, uterine specimens, and, when available, tumor samples. The planned analyses included evaluation of the potential risk factors for EC/OC; evaluation of molecular biomarkers in minimally invasive samples; evaluation of the cost-effectiveness of molecular tests; and the generation of predictive scores to integrate different epidemiologic, clinical, and molecular factors. Overall, 182 EC, 69 OC, 98 BRCA pathogenic variant carriers, 104 MMR pathogenic variant carriers, and 385 controls were enrolled. The overall participation rate was 85.7%. The pilot study using 61 samples from nine EC cases and four controls showed that genetic variants at the variant allele fraction > 5% found in tumors (n = 61 variants across the nine tumors) were detected in paired endometrial aspirates, clinician-collected cervical samples, and vaginal self-samples with detection rates of 90% (55/61), 79% (48/61), and 72% (44/61) by duplex sequencing, respectively. Among the controls, only one somatic mutation was detected in a cervical sample. We enrolled more than 800 women to evaluate new early detection strategies. The preliminary data suggest that our methodological approach could be useful for the early detection of gynecological cancers.

1 August 2019 in Cancer Epidemiology
Verified
Journal Article
Closed access
LCLaura Costas
Laura Costas
LPLuis Palomero
Luis Palomero
YBYolanda Benavente
Yolanda Benavente
MGMagdalena Guardiola
Magdalena Guardiola
JFJon Frias-Gomez
Jon Frias-Gomez
ÁAÁlvaro Aytés
Álvaro Aytés